The efficacy and toxicity of readministration of rituximab (Rituxan) in patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that recurs after an initial response to rituximab are unknown.
The efficacy and toxicity of readministration of rituximab (Rituxan) in patients with indolent B-cell non-Hodgkins lymphoma (NHL) that recurs after an initial response to rituximab are unknown. We conducted a multicenter, phase II study of rituximab in indolent CD20-positive B-cell NHL. The present study attempts to investigate the safety and efficacy of readministration of rituximab.
From July 1997 to November 1998, patients with relapsed, indolent, CD20-positive B-cell NHL, revised European-American Lymphoma (REAL) type II-1, 2, 3, 4, 5, and 6 histology, all of whose pathology was confirmed by central review, were treated with rituximab at 375 mg/m² × 4 weekly infusions as a phase II study in Japan. Rituximab produced a 59% response rate (95% confidence interval [CI], 41% to 71%) Retreatment was planned for responsive patients who showed stable disease (SD), partial response (PR), or complete response (CR) after the initial treatment. To be eligible for retreatment, patients were required to meet the same criteria as for a phase II study.
Nine patients were retreated with identical courses of rituximab. Five patients who received rituximab (250 or 375 mg/m² × 4 weekly infusions) in the preceding phase I study were also entered into this study. All 14 patients eligible for retreatment had stage IIIA or IVA disease and had an International Prognostic Index (IPI), placing them in a low- or low-intermediate risk group. The median follow-up time was 19 months (range, 15 to 33 months). Of the 14 patients, 11 had follicular lymphoma; 1, mantle cell lymphoma; and 2, diffuse large B-cell lymphoma.
Rituximab retreatment was well tolerated, with no grade 3-4 nonhematologic toxicity, similar to initial therapy. One patient developed grade 3 neutropenia. One patient died of disease progression. All patients experienced rapid B-cell decrease, which lasted for more than 4 months. No patient developed human antimouse antibody (HAMA) and human antichimeric antibody (HACA) reactions after retreatment. T-cell counts and serum immunoglobulin levels did not decrease during the follow-up period.
Responses to retreatment were seen in 5 of 14 patients (36%; 95% CI,12% to 64%); 7patients had SD; and 2 experienced progressive disease (PD). Overall survival rate was 93% at 19 months. Median time to progression (TTP) after retreatment was 5 months, while median TTP after initial treatment was 8 months.
There was no significant correlation between TTP after initial treatment and that after the second treatment. Three patients who received more than three courses of retreatment continue to show response.
CONCLUSION: Rituximab is effective for relapsed, indolent, CD20-positive B-cell NHL after initial rituximab treatment and can produce prolonged failure-free survival without major toxicities.
Click here for Dr. Bruce Chesons commentary on this abstract.